Colleen Kusy
Stock Analyst at Baird
(1.71)
# 3,334
Out of 4,981 analysts
49
Total ratings
32.56%
Success rate
-9.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLYM Climb Bio | Initiates: Outperform | $9 | $2.25 | +300.00% | 1 | Aug 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $47 → $50 | $24.85 | +101.21% | 12 | Jul 18, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $105 → $112 | $80.54 | +39.06% | 2 | Jun 25, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $19.96 | +160.52% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $4.48 | +33.93% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $17.40 | +135.63% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.29 | +365.12% | 5 | Dec 5, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $15.65 | +315.34% | 2 | Nov 13, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $100 → $75 | $7.14 | +950.42% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $12.81 | +32.71% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $10.78 | +131.91% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $6.45 | +3,155.81% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.27 | +1,397.80% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $2.12 | +10,749.06% | 1 | Nov 2, 2021 |
Climb Bio
Aug 15, 2025
Initiates: Outperform
Price Target: $9
Current: $2.25
Upside: +300.00%
Apellis Pharmaceuticals
Jul 18, 2025
Maintains: Outperform
Price Target: $47 → $50
Current: $24.85
Upside: +101.21%
Nuvalent
Jun 25, 2025
Maintains: Outperform
Price Target: $105 → $112
Current: $80.54
Upside: +39.06%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $19.96
Upside: +160.52%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $4.48
Upside: +33.93%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $17.40
Upside: +135.63%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.29
Upside: +365.12%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $15.65
Upside: +315.34%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $100 → $75
Current: $7.14
Upside: +950.42%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $12.81
Upside: +32.71%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $10.78
Upside: +131.91%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $6.45
Upside: +3,155.81%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.27
Upside: +1,397.80%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $2.12
Upside: +10,749.06%